SALINOMYCIN SODIUM SALT 2.5-HYDRATE;SALINOMYCIN SV SODIUM SALT 2,5-HYDRATE;Salinomycin hydrate monosodium salt;Salinomycin, monosodium salt;salinomycin monosodium salt hydrate;Salinomycin-Natrium;(2R)-2-[(5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5R,7S,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-Ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5.3]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid;Salinomycin 1-sodium salt
Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
Safety Information
Symbol(GHS)
Signal word
Danger
Hazard statements
H301：Toxic if swalloed
Precautionary statements
P264：Wash hands thoroughly after handling.
P264：Wash skin thouroughly after handling.
P270：Do not eat, drink or smoke when using this product.
P301+P310：IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P405：Store locked up.
P501：Dispose of contents/container to..…
Description
Cancer stems cells (CSCs) are a subpopulation of cells within tumors that drive tumor growth and recurrence. They are resistant to many current cancer treatments. Salinomycin (sodium salt) is an antibacterial and coccidiostat compound that shows selective toxicity for the CSCs that exist as a subpopulation within HMLER breast cancer cells (IC50s = ~24 versus ~90 μM). At 8 μM, salinomycin treatment of 4T1 and MCF-7-Ras breast cancer cell lines results in a ~2-fold and ~3-fold, respective reduction of CSCs relative to controls. Treatment of 5 mg/kg salinomycin in mice implanted with SUM159 human breast cancer cells inhibits mammary tumor growth and induces increased epithelial differentiation of tumor cells.
